345 related articles for article (PubMed ID: 24120066)
21. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
22. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
23. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
24. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study.
Hunger SP; Fall MZ; Camitta BM; Carroll AJ; Link MP; Lauer SJ; Mahoney DH; Pullen DJ; Shuster JJ; Steuber CP; Cleary ML
Blood; 1998 Feb; 91(3):1021-8. PubMed ID: 9446665
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
26. Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Seyfarth J; Madsen HO; Nyvold C; Ryder LP; Clausen N; Jonmundsson GK; Wesenberg F; Schmiegelow K
Med Pediatr Oncol; 2003 Feb; 40(2):82-7. PubMed ID: 12461790
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].
Liu F; Chen XJ; Guo Y; Yang WY; Chen X; Zhang XY; Zhang RR; Ren YY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):896-902. PubMed ID: 33333691
[No Abstract] [Full Text] [Related]
28. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
29. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
[TBL] [Abstract][Full Text] [Related]
30. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
31. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
33. [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
Lan Y; Chen XJ; Zou Y; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2019 May; 21(5):405-410. PubMed ID: 31104652
[TBL] [Abstract][Full Text] [Related]
34. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].
Wu CP; Zheng YZ; Li J; Wen H; Weng KZ; Zhuang SQ; Wu XG; Hua XL; Zheng H; Chen ZS; LE SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):6-13. PubMed ID: 38387892
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Results of the Risk-Stratified Treatment of TCF3-PBX1-Positive Pediatric Acute Lymphoblastic Leukemia in China.
Wang Y; Xue YJ; Lu AD; Jia YP; Zuo YX; Zhang LP
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e137-e144. PubMed ID: 33221150
[TBL] [Abstract][Full Text] [Related]
37. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
[TBL] [Abstract][Full Text] [Related]
38. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
Yetgin S; Tuncer MA; Cetin M; Gümrük F; Yenicesu I; Tunç B; Oner AF; Toksoy H; Koç A; Aslan D; Ozyürek E; Olcay L; Atahan L; Tunçbilek E; Gürgey A
Leukemia; 2003 Feb; 17(2):328-33. PubMed ID: 12592331
[TBL] [Abstract][Full Text] [Related]
39. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
[TBL] [Abstract][Full Text] [Related]
40. Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia.
Wiemels JL; Leonard BC; Wang Y; Segal MR; Hunger SP; Smith MT; Crouse V; Ma X; Buffler PA; Pine SR
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15101-6. PubMed ID: 12415113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]